Normal brain aging and Alzheimer's disease are associated with lower cerebral pH: an in vivo histidine H-1-MR spectroscopy study

It is unclear whether alterations in cerebral pH underlie Alzheimer's disease (AD) and other dementias. We performed proton spectroscopy after oral administration of histidine in healthy young and elderly persons and in patients with mild cognitive impairment and dementia (total N = 147). We me...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurobiology of aging 2020-03, Vol.87, p.60-69
Hauptverfasser: Lyros, Epameinondas, Ragoschke-Schumm, Andreas, Kostopoulos, Panagiotis, Sehr, Alexandra, Backens, Martin, Kalampokini, Stefania, Decker, Yann, Lesmeister, Martin, Liu, Yang, Reith, Wolfgang, Fassbender, Klaus
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:It is unclear whether alterations in cerebral pH underlie Alzheimer's disease (AD) and other dementias. We performed proton spectroscopy after oral administration of histidine in healthy young and elderly persons and in patients with mild cognitive impairment and dementia (total N = 147). We measured cerebral tissue pH and ratios of common brain metabolites in relation to phosphocreatine and creatine (Cr) in spectra acquired from the hippocampus, the white matter (WM) of the centrum semiovale, and the cerebellum. Hippocampal pH was inversely associated with age in healthy participants but did not differ between patients and controls. WM pH was low in AD and, to a lesser extent, mild cognitive impairment but not in frontotemporal dementia spectrum disorders and pure vascular dementia. Furthermore, WM pH provided incremental diagnostic value in addition to N-acetylaspartate to Cr ratio. Our study suggests that in vivo assessment of pH may be a useful marker for the differentiation between AD and other types of dementia. (C) 2019 Elsevier Inc. All rights reserved.
ISSN:0197-4580
1558-1497
DOI:10.1016/j.neurobiolaging.2019.11.012